| IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease. | |
| | |
MedLine Citation:
|
PMID: 20424802 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The Fifth International Pharmaco-Economic Conference on Alzheimer's Disease was held in New York, on March 27-29 in 2008. The attendees included researchers and key opinion leaders within the academia, pharmaceutical industry, patient organizations and regulatory bodies, collecting the worldwide leading expertise in Alzheimer research today. A summary of the presentations and conclusions from the discussions are presented in this publication. Pharmaco-economics need to play a leading role in developing and communicating evidence of the value of anti-dementia drugs, now and in the future. For the development of evidence, the challenges include transparency and standardization of costs of care assessment, improved diagnostics for identifying target patient groups, improved endpoints for assessing outcomes and improved models for assessing the long term consequences of competing treatment strategies. For the communication of evidence, the challenge lies in convincing decision makers to recognize the integrated burden of the disease, including its interaction with co-morbidities and burden on caregivers, and to consider the consequences of competing treatment strategies from a societal perspective. |
| | |
Authors:
|
A Gustavsson; L Jonsson; H Fillit; G Johansson; A Wimo; B Winblad |
Publication Detail:
|
Type: Congresses |
Journal Detail:
|
Title: The journal of nutrition, health & aging Volume: 14 ISSN: 1760-4788 ISO Abbreviation: J Nutr Health Aging Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-28 Completed Date: 2010-06-16 Revised Date: 2010-10-12 |
Medline Journal Info:
|
Nlm Unique ID: 100893366 Medline TA: J Nutr Health Aging Country: France |
Other Details:
|
Languages: eng Pagination: 358-60 Citation Subset: IM |
Affiliation:
|
KI Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska institutet, Novum plan 5, 141 86 Stockholm, Sweden. anders.gustavsson@ki.se |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Alzheimer Disease / diagnosis, drug therapy, economics* Cost-Benefit Analysis Evidence-Based Medicine Health Care Costs* Humans Middle Aged Models, Economic Neuroprotective Agents / economics*, therapeutic use Nootropic Agents / economics*, therapeutic use Randomized Controlled Trials as Topic Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Neuroprotective Agents; 0/Nootropic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Day care at green care farms: a novel way to stimulate dietary intake of community-dwelling older pe...
Next Document: Skeletal muscle fat infiltration: impact of age, inactivity, and exercise.